{"id":"NCT01910402","sponsor":"ViiV Healthcare","briefTitle":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","officialTitle":"A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-22","primaryCompletion":"2015-09-22","completion":"2022-08-18","firstPosted":"2013-07-29","resultsPosted":"2016-10-31","lastUpdate":"2024-02-20"},"enrollment":499,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Infection, Human Immunodeficiency Virus","HIV Infections"],"interventions":[{"type":"DRUG","name":"Dolutegravir/abacavir/lamivudine FDC","otherNames":[]},{"type":"DRUG","name":"Atazanavir","otherNames":[]},{"type":"DRUG","name":"Ritonavir","otherNames":[]},{"type":"DRUG","name":"Tenofovir/emtricitabine FDC","otherNames":[]}],"arms":[{"label":"DTG/ABC/3TC FDC","type":"EXPERIMENTAL"},{"label":"ATV +RTV +TDF/FTC FDC","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC) OD in HIV-1 infected, ART-naïve women over 48 weeks. This study will also characterize the safety and tolerability of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC. Sufficient number of subjects will be screened in order to ensure a total of approximately 474 subjects will be randomized (237 in each study arm)","primaryOutcome":{"measure":"Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"DTG 50 mg/ABC 600 mg/3TC 300 mg QD-Randomized Phase","deltaMin":82,"sd":null},{"arm":"ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD-Randomized Phase","deltaMin":71,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":90,"countries":["United States","Argentina","Canada","France","Italy","Mexico","Portugal","Puerto Rico","Russia","South Africa","Spain","Thailand","United Kingdom"]},"refs":{"pmids":["28729158"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":248},"commonTop":["Nausea","Headache","Diarrhoea","Upper respiratory tract infection","Urinary tract infection"]}}